There is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
| Orders | Qty | Bid |
|---|---|---|
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| Ask | Qty | Orders |
|---|---|---|
| 1945 | 4 | 628 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
Annual Revenue,rose 22.22%, in the last year to ₹6,861.28 Cr. Its sector's average revenue growth for the last fiscal year was 12.2%.Annual Net Profit,rose 148.04% in the last year to ₹888.79 Cr. Its sector's average net profit growth for the last fiscal year was 1.93%.Quarterly Revenue,rose 29.1% YoY to ₹2,035.49 Cr. Its sector's average revenue growth YoY for the quarter was 15.53%.
Laurus Labs Limited is a research-driven, integrated pharmaceutical company engaged across Contract Development and Manufacturing (CDMO), Generics Finished Dosage Forms (FDF), Active Pharmaceutical Ingredients (APIs), and Biotechnology. Its offerings span development to large-scale manufacturing for pharma, biotech, animal health, crop science and specialty ingredients, supported by state-of-the-art R&D and compliant manufacturing facilities. The company serves a global customer base with products distributed in 80+ countries, with 68 Per cent of revenue from exports and a regional mix of 20 Per cent North America, 25 Per cent Europe and 55 Per cent Rest of World . As on the reporting date, Laurus Labs has 8 subsidiaries (including step-down subsidiaries) .
Key milestones and profile highlights:
– Established expertise in complex chemistry and advanced manufacturing, including India’s large Hi-Potent API capabilities and leadership in antiretroviral APIs .
– A diversified portfolio now includes integrated API/FDF development and microbial precision fermentation through its biotech arm .
– 15 development and manufacturing sites and five R&D centres supporting global supply and innovation pipelines .
– Trusted by 250+ global customers, with products distributed in 80+ countries .
– Revenue contribution by division (FY25): Generics (API and FDF) 72 Per cent; CDMO 25 Per cent; Biotechnology 3 Per cent .
– Revenue contribution by geography: 68 Per cent exports; 32 Per cent domestic. Regional mix: 20 Per cent North America, 25 Per cent Europe and 55 Per cent Rest of World .
– Dr. K. Ravindranath – Non-Executive Chairman and Independent Director .
– Dr. Satyanarayana Chava – Executive Director & Chief Executive Officer .
– Mr. V. V. Ravi Kumar – Executive Director & Chief Financial Officer .
– Dr. C. V. Lakshmana Rao – Executive Director – Quality .
– Mr. Krishna Chaitanya Chava – Executive Director – Synthesis .
– Ms. Soumya Chava – Executive Director – Generics .
– G. Venkateswar Reddy – Company Secretary & Compliance Officer .
– Opened a 200,000 sq. ft. small-molecule R&D centre at IKP Knowledge Park, Telangana in September 2024, established with an initial investment of Rs 250 crore, and expected to create employment for over 800 professionals in two years .
– Laurus Bio secured an equity investment of Rs 120 crore from Eight Roads Ventures and F-Prime Capital, with Laurus Labs co-investing Rs 40 crore in December 2024 to expand microbial fermentation capabilities for bio-based proteins and enzymes .
– Formed a joint venture, KRKA Pharma Private Limited, with a 49 Per cent stake; investment of Rs 105.35 crore, accounted as a joint venture with effect from October 03, 2024 .
– Commissioned a new Drug Substance block at Unit-4; Animal Health DS facility (LSLP-U2) made operational (MB-3), with MB-4 under construction; Agrochemicals facility at LSPL Unit-4 brought online .
– Received Establishment Inspection Reports for the Unit 4 API facility and completed 160+ quality audits in FY25 with no critical findings .
– Recognitions: 2024 DET Hurun Award; named among India’s top 75 innovative companies by CII; Export Performance Award at IPHEX; multiple safety and manufacturing excellence awards for Units 1–3 .
As of 10 Sep 2026, the share price of Laurus Labs Limited is ₹1,945.00 on the NSE and ₹1,936.00 on the BSE. The stock opened at ₹1,932.60, touched a high of ₹1,955.00 and a low of ₹1,790.00 during today's session.
Over the last 6 months, Laurus Labs Limited has given a return of 86.61%. The stock was priced at ₹1,038.00 on 10 Mar 2026 and has Rise to ₹1,945.00 as of 10 Sep 2026, a change of ₹907.00 per share.
Laurus Labs Limited has delivered 116.09% return over the last 52 weeks. During this period, the stock hit a 52-week high of ₹1,955.00 on 09 Sep 2026 and a 52-week low of ₹823.10 on 26 Sep 2025. It is currently trading at ₹1,945.00 as of 10 Sep 2026.
The all-time high (ATH) for Laurus Labs Limited was ₹1,946.90, recorded on 08 Sep 2026. At the current price of ₹1,945.00, the stock is trading 0.10% below its all-time high. The all-time low recorded was ₹62.05 on 17 Oct 2019.
Laurus Labs Limited has delivered a 199.98% absolute return over the past 5 years, equivalent to a CAGR of 24.57% per annum. The stock was priced at ₹648.38 in Sep 2021 and has risen to ₹1,945.00 as of 10 Sep 2026. An investment of ₹1,00,000 in Laurus Labs Limited five years ago would be worth ₹2,99,980.00 today.
Yes,Laurus Labs Limited has declared a consistent dividend every year over the past 5 years. The company paid a total dividend of 7.20 per share between FY2022 and FY2026, with the most recent dividend of ₹1.20 per share for Apr 26, with an ex-dividend date of 08 May 2026. At the current market price of ₹1,945.00, the trailing dividend yield of Laurus Labs Limited stands at 2.80%.
Laurus Labs Limited has delivered a return of 39.78% over the last 3 months. The stock was trading at ₹1,385.70 on 10 Jun 2026 and is currently at ₹1,945.00 as of 10 Sep 2026, reflecting a Gain of ₹559.30 per share over this period.
The intraday low for Laurus Labs Limited on the NSE today was ₹1,790.00. The stock's 52-week low stands at ₹823.10, recorded on 26 Sep 2025. Today's low is 117.47% above the 52-week low, indicating the stock is trading well above its yearly lows.
The intraday high for Laurus Labs Limited on the NSE today (10 Sep 2026) was ₹1,955.00. This compares to the 52-week high of ₹1,955.00 recorded on 09 Sep 2026. Today's high was 0.00% above the 52-week high.
For Q1 FY27, Laurus Labs Limited reported: Revenue (Net Sales): ₹17571.60 Cr - Up 11.19% year-on-year from ₹15803.00 Cr in Q4 FY26. Net Income (PAT): ₹2899.60 Cr - Up 51.19% year-on-year from ₹1917.90 Cr in Q4 FY26.
